Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a report issued on Thursday. They currently have a GBX 271 ($3.54) target price on the stock. Stifel Nicolaus’ target price points to a potential upside of 125.83% from the stock’s current price.
Ergomed PLC (LON:ERGO) opened at 120.555 on Thursday. Ergomed PLC has a 12 month low of GBX 117.00 and a 12 month high of GBX 173.74. The firm has a 50-day moving average price of GBX 119.97 and a 200 day moving average price of GBX 136.49. The company’s market capitalization is GBX 34.66 million.
About Ergomed PLC
Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.
Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.